Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

With €66M series A, T-knife to bring four TCR therapies into the clinic by 2022

August 6, 2020 11:30 AM UTC

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate human, high affinity TCRs.

The Berlin-based company spun out of the Max-Delbrück Center for Molecular Medicine in 2018 with €8 million in seed funding from founding investors Andera Partners and Boehringer Ingelheim Venture Fund and IP covering its humanized TCR mouse technology...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article